FMC
FMC CORPORATION
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$3.5B
Operating marginCalculated
-47.0%
Net assets to total assetsCalculated
21.4%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★☆☆☆☆position among all companies
-47.0%
Growth (revenue, 4-year average)
★☆☆☆☆position among all companies
-8.9%
Capital efficiency
★☆☆☆☆position among all companies
-108.1%
Revenue and profit
Performance, financial position and capital allocation
FMC
Recent performance trends
FMC
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$5.0 billion | US$5.8 billion | US$4.5 billion | US$4.2 billion | US$3.5 billion |
| Operating income | US$1.0 billion | US$1.1 billion | US$0.6 billion | US$0.5 billion | US$-1.6 billion |
| Net income | US$0.7 billion | US$0.7 billion | US$1.3 billion | US$0.3 billion | US$-2.2 billion |
| Total assets | US$10.7 billion | US$11.2 billion | US$11.9 billion | US$11.7 billion | US$9.7 billion |
| Shareholders' equity | US$3.1 billion | US$3.4 billion | US$4.4 billion | US$4.5 billion | US$2.1 billion |
| Net cash provided by (used in) operating activities | US$0.9 billion | US$0.7 billion | US$-0.3 billion | US$0.7 billion | US$-6.20 million |
| Net cash provided by (used in) investing activities | Could not be retrieved | US$-0.3 billion | US$-0.2 billion | US$0.3 billion | US$-99.70 million |
| Net cash provided by (used in) financing activities | US$-0.7 billion | US$-0.2 billion | US$0.3 billion | US$-0.9 billion | US$0.4 billion |
| Cash and cash equivalents | US$0.5 billion | US$0.6 billion | US$0.3 billion | US$0.4 billion | US$0.6 billion |
Revenue scale in the same industry
FMC
Chemicals and pharmaceuticals: 56 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Johnson & JohnsonFY Dec 2025 US$94.2B
- 2 Procter & GambleFY Jun 2026 US$87.0B
- 3 ELI Lilly ANDFY Dec 2025 US$65.2B
- … 46 companies
- 50 CabotFY Sep 2025 US$3.7B
- 51 Fuller H BFY Nov 2025 US$3.5B
- 52 FMCThis companyFY Dec 2025 US$3.5B
- 53 Scotts Miracle-GroFY Sep 2025 US$3.4B
- 54 AvientFY Dec 2025 US$3.3B
- … 2 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$96.30 million | Consolidated | Disclosed |
| Cash and cash equivalents | US$0.6 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$0.4 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-99.70 million | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$-6.20 million | Consolidated | Disclosed |
| Depreciation and amortization | US$0.2 billion | Consolidated | Disclosed |
| Dividends paid | US$0.3 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$2.1 billion | Consolidated | Disclosed |
| Non-controlling interests | US$27.40 million | Consolidated | Disclosed |
| Net assets | US$2.1 billion | Consolidated | Disclosed |
| Net sales | US$3.5 billion | Consolidated | Disclosed |
| Operating income | US$-1.6 billion | Consolidated | Disclosed |
| Net income | US$-2.2 billion | Consolidated | Disclosed |
| Total assets | US$9.7 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$0 | Consolidated | Disclosed |
| Operating margin | -47.0% | Consolidated | Calculated |
| Net assets to total assets | 21.4% | Consolidated | Calculated |
| Net margin | -64.6% | Consolidated | Calculated |
| Return on equity | -108.1% | Consolidated | Calculated |